Summary of share price highs, lows and changes for Calidi Biotherapeutics
Historical stock prices
Current Share Price	US$0.21
52 Week High	US$19.20
52 Week Low	US$0.19
Beta	1.42
1 Month Change	-12.76%
3 Month Change	-80.13%
1 Year Change	-96.40%
3 Year Change	-99.90%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	CLDI	US Biotechs	US Market
7D	-9.8%	-4.3%	-0.2%
1Y	-96.4%	27.9%	27.6%

Return vs Industry: CLDI underperformed the US Biotechs industry which returned 28.8% over the past year.

Return vs Market: CLDI underperformed the US Market which returned 29.1% over the past year.

Price Volatility

Is CLDI's price volatile compared to industry and market?
CLDI volatility
CLDI Average Weekly Movement	17.9%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.3%

Stable Share Price: CLDI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CLDI's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	29	Eric Poma	www.calidibio.com

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova.

Calidi Biotherapeutics, Inc. Fundamentals Summary

How do Calidi Biotherapeutics's earnings and revenue compare to its market cap?
CLDI fundamental statistics
Market cap	US$2.30m
Earnings (TTM)	-US$25.58m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is CLDI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLDI income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$25.58m
Earnings	-US$25.58m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.32
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	16.0%

How did CLDI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/29 09:12
End of Day Share Price	2026/04/29 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Calidi Biotherapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Aydin Huseynov	Ladenburg Thalmann & Company

Calidi Biotherapeutics (CLDI) Stock Overview

Risk Analysis

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Calidi Biotherapeutics, Inc. Competitors

Aptevo Therapeutics

Oragenics

Matinas BioPharma Holdings

Biodexa Pharmaceuticals

Price History & Performance

Recent News & Updates

Calidi Biotherapeutics Presents New Data on Cld-401 At the Aacr Annual Meeting

Calidi Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2026

Calidi Biotherapeutics to Presents New Data on Differentiated Approach to in Situ T-Cell Engagers Including New Candidate Targeting Trop-2

Calidi Biotherapeutics Presents Innovative And Scalable Manufacturing Process For CLD-401

New major risk - Share price stability

Calidi Biotherapeutics, Inc. has completed a Composite Units Offering in the amount of $10.519632 million.

Recent updates

Calidi Biotherapeutics Presents New Data on Cld-401 At the Aacr Annual Meeting

Calidi Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2026

Calidi Biotherapeutics to Presents New Data on Differentiated Approach to in Situ T-Cell Engagers Including New Candidate Targeting Trop-2

Calidi Biotherapeutics Presents Innovative And Scalable Manufacturing Process For CLD-401

New major risk - Share price stability

Calidi Biotherapeutics, Inc. has completed a Composite Units Offering in the amount of $10.519632 million.

Calidi Biotherapeutics, Inc. Presents Data on its New Approach to Bispecific T-Cell Engagers Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi Biotherapeutics, Inc. to Present on Its New Approach to Bispecific T-Cell Engagers Using Its Redtail Platform in A Late-Breaking Abstract At the 2026 Aacr-Io Conference

High number of new and inexperienced directors

Calidi Biotherapeutics, Inc. Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics, Inc. Announces Establishment of Scientific Advisory Board

New major risk - Market cap size

Calidi Biotherapeutics, Inc. has completed a Composite Units Offering in the amount of $6 million.

Calidi Biotherapeutics, Inc. Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

New major risk - Market cap size

Calidi Biotherapeutics Inc. Presents Systemic Oncolytic Platform with Cd55-Enhanced Expression and Il-15 Superagonist Payload At Asco Annual Meeting

New major risk - Financial position

Calidi Biotherapeutics, Inc., Annual General Meeting, Jul 01, 2025

Calidi Biotherapeutics Inc. Announces IL15 Superagonist as First Payload to Be Delivered by Systemic Antitumor Virotherapy Platform At AACR Annual Meeting

Calidi Biotherapeutics Inc. Announces Chief Executive Officer Changes, Effective April 22, 2025

Calidi Biotherapeutics, Inc. Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Calidi Biotherapeutics Inc. Appoints Guy Travis Clifton as Chief Medical Officer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.931722 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.931722 million.

Calidi Biotherapeutics and City of Hope Provide Update on A Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics Announces Demonstrated Ability to Deliver Transient Gene Therapy (Payload) to Tumors Using Systemic Platform

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose Cld-101 Trial in Patients with Newly Diagnosed High Grade Glioma At Northwestern University Hospital

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. executed a term sheet to acquire First Light Acquisition Group, Inc. (NYSEAM:FLAG) from group of sellers in a reverse merger transaction.

Shareholder Returns